Insider Selling: AxoGen, Inc. (NASDAQ:AXGN) Insider Sells 2,652 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) insider Maria D. Martinez sold 2,652 shares of the stock in a transaction dated Friday, June 4th. The shares were sold at an average price of $18.86, for a total transaction of $50,016.72. Following the completion of the transaction, the insider now owns 2,932 shares of the company’s stock, valued at approximately $55,297.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of NASDAQ AXGN opened at $19.69 on Friday. AxoGen, Inc. has a twelve month low of $8.77 and a twelve month high of $23.94. The company has a quick ratio of 5.47, a current ratio of 6.07 and a debt-to-equity ratio of 0.44. The firm has a market cap of $807.35 million, a P/E ratio of -35.80 and a beta of 0.69. The firm has a 50-day simple moving average of $19.91.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Tuesday, May 4th. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.12. AxoGen had a negative net margin of 18.69% and a negative return on equity of 17.69%. The company had revenue of $31.04 million during the quarter, compared to the consensus estimate of $28.65 million. On average, sell-side analysts anticipate that AxoGen, Inc. will post -0.68 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of AXGN. NEXT Financial Group Inc acquired a new stake in AxoGen in the 4th quarter valued at about $29,000. Thompson Siegel & Walmsley LLC purchased a new stake in AxoGen during the fourth quarter valued at about $50,000. Lazard Asset Management LLC lifted its stake in AxoGen by 238.1% during the fourth quarter. Lazard Asset Management LLC now owns 3,090 shares of the medical equipment provider’s stock valued at $55,000 after buying an additional 2,176 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in AxoGen during the first quarter valued at about $90,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new stake in AxoGen during the first quarter valued at about $101,000. 75.69% of the stock is owned by institutional investors.

A number of equities analysts recently issued reports on AXGN shares. Canaccord Genuity reiterated a “hold” rating and issued a $24.00 target price on shares of AxoGen in a research report on Tuesday, May 25th. SVB Leerink reiterated a “buy” rating and issued a $27.00 target price on shares of AxoGen in a research report on Monday, May 31st. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. AxoGen currently has an average rating of “Buy” and a consensus price target of $24.50.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

See Also: What is a Futures Contract?

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.